Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-65 years.~2. Able to provide informed consent.~3. Patients hospitalized with pneumonia proved by chest X-ray or CT scan.~4. Confirmed infection with COVID-2019 using RT-PCR or strongly suspected to be infected with pending confirmation studies.~5. Hyper-inflammation defined as elevation in either C-reactive protein (CRP, ≥ 100 mg/L, normal values \<6 mg/L) or ferritin (≥ 900 ng/mL, normal value \<400 ng/mL), in the presence of increased lactate dehydrogenase (LDH, \>220 U/L).~6. And at least one of the following:~   1. Respiratory frequency ≥30/min.~  2. Blood oxygen saturation ≤93% on room air (RA).~  3. Partial pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO2/FiO2) \<300 \[18\].~  4. Worsening of lung involvement, defined as an increase in number and/or extension of pulmonary areas of consolidation, need for increased FiO2 to maintain stable O2 saturation, or worsening O2 saturation of \>3% with stable FiO2.~Exclusion Criteria:~1. Evidence of concomitant bacterial infection.~2. Concomitant use of other immunosuppressive biologic drugs.~3. Baseline elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels \> 5-fold the upper limit of the normal range.~4. Pregnancy.~5. Treatment with any TNFα inhibitor in the past 30 days.~6. Known hypersensitivity to any TNFα inhibitor, murine proteins, or any component of the formulation.~7. Known or suspected active tuberculosis (TB) or a history of incompletely treated or latent TB.~8. Serious co-morbidity, including:~   1. Myocardial infarction (within last month).~  2. Moderate or severe heart failure (New York Heart Association (NYHA) class III or IV).~  3. Hepatic patients child Pugh class C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: None

Study Arms:
- Group 1 (Type: None): Moderate and severe patients who were infected with SARS-CoV-2 and received treatment with tocilizumab in addition to standard management.
- Group 2 (Type: None): Moderate and severe patients who were infected with SARS-CoV-2 and received treatment with infliximab and tocilizumab in addition to standard management.

Based on this trial design, predict the completion outcome and termination type (if applicable).